📊 CYRX Key Takeaways
Investment Thesis
Cryoport exhibits a paradoxical financial profile with strong profitability metrics (44.4% net margin, 15.6% ROE) but severe operational weakness (-20.9% operating margin, -$25M free cash flow). The 11.4% net income growth is driven by non-operating gains rather than core business improvement, and negative operating cash flow signals fundamental business sustainability concerns despite reported profitability.
CYRX Strengths
- Strong net profit margin of 44.4% demonstrates pricing power and efficient cost management at bottom line
- Healthy balance sheet with $250.5M cash, 2.17x current ratio, and conservative 0.23x debt/equity ratio providing financial flexibility
- Solid gross margin of 47.1% indicates competitive products and strong demand in pharmaceutical logistics segment
CYRX Risks
- Severe operating loss of $36.8M with -20.9% operating margin indicates core business is unprofitable despite net income gains
- Negative free cash flow of -$25M with -$8.6M operating cash flow raises red flags about earnings quality and sustainability
- Disconnect between reported net income growth and operational deterioration suggests one-time gains or accounting adjustments masking business decline
- Negative interest coverage ratio of -27.5x indicates inability to service debt from operations
Key Metrics to Watch
- Operating cash flow trend and path to positive FCF generation
- Operating income trajectory and operating margin expansion/contraction
- Revenue growth sustainability and gross margin stability
- Quality of earnings analysis to isolate operating vs non-operating income components
CYRX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.17x current ratio provides a solid financial cushion.
CYRX Profitability Ratios
CYRX vs Healthcare Sector
How Cryoport, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CYRX Balance Sheet & Liquidity
CYRX 5-Year Financial Trend
5-Year Trend Summary: Cryoport, Inc.'s revenue has declined by 26% over the 5-year period, indicating business contraction. The most recent EPS of $-2.21 indicates the company is currently unprofitable.
CYRX Growth Metrics (YoY)
CYRX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $38.3M | $805.0K | $-0.02 |
| Q2 2025 | $39.7M | -$78.0M | $-1.62 |
| Q1 2025 | $37.3M | -$12.0M | $-0.28 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CYRX Capital Allocation
CYRX SEC Filings
Access official SEC EDGAR filings for Cryoport, Inc. (CIK: 0001124524)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CYRX
What is the AI rating for CYRX?
Cryoport, Inc. (CYRX) has an AI rating of HOLD with 55% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CYRX's key strengths?
Strong net profit margin of 44.4% demonstrates pricing power and efficient cost management at bottom line. Healthy balance sheet with $250.5M cash, 2.17x current ratio, and conservative 0.23x debt/equity ratio providing financial flexibility.
What are the risks of investing in CYRX?
Severe operating loss of $36.8M with -20.9% operating margin indicates core business is unprofitable despite net income gains. Negative free cash flow of -$25M with -$8.6M operating cash flow raises red flags about earnings quality and sustainability.
What is CYRX's revenue and growth?
Cryoport, Inc. reported revenue of $176.2M.
Does CYRX pay dividends?
Cryoport, Inc. does not currently pay dividends.
Where can I find CYRX SEC filings?
Official SEC filings for Cryoport, Inc. (CIK: 0001124524) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CYRX's EPS?
Cryoport, Inc. has a diluted EPS of $1.40.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.